Cytogenetic effects of an alkyl-lysophospholipid derivative in human peripheral lymphocytes exposed in vitro and in vivo.
Chromosome analyses were carried out in human lymphocytes exposed to an antitumor alkyl-lysophospholipid (ALP) in vitro and in vivo. There was no evidence for a significant clastogenic effect or incidence of an increased sister-chromatid exchange (SCE) after short-term and long-term treatment of unstimulated or stimulated lymphocytes with concentrations of 0.1-50 micrograms ALP per ml. Cell proliferation was delayed after G0 exposure to 50 micrograms/ml. Although no ALP monotherapy was present for 3 cancer patients examined before and during ALP treatment with accumulated doses of 15-516 mg/kg, the cytogenetic data were in accord with the negative experimental results.
D000970:Antineoplastic Agents / Q000494:pharmacology*; D006801:Humans; D007399:Interphase; D008214:Lymphocytes / Q000187:drug effects*; D008246:Lysophospholipids; D009152:Mutagenicity Tests; D010743:Phospholipids / Q000494:pharmacology*; D012854:Sister Chromatid Exchange / Q000187:drug effects
D000970:Antineoplastic Agents; D008246:Lysophospholipids; D010743:Phospholipids